St.Gallen consensus on safe implementation of transanal total mesorectal excision
- PMID: 29234940
- PMCID: PMC5807525
- DOI: 10.1007/s00464-017-5990-2
St.Gallen consensus on safe implementation of transanal total mesorectal excision
Abstract
Background: The management of rectal cancer has evolved over the years, including the recent rise of Transanal Total Mesorectal Excision (TaTME). TaTME addresses the limitations created by the bony confines of the pelvis, bulky tumours, and fatty mesorectum, particularly for low rectal cancers. However, guidance is required to ensure safe implementation and to avoid the pitfalls and potential major morbidity encountered by the early adopters of TaTME. We report a broad international consensus statement, which provides a basis for optimal clinical practice.
Methods: Forty international experts were invited to participate based on clinical and academic achievements. The consensus statements were developed using Delphi methodology incorporating three successive rounds. Consensus was defined as agreement by 80% or more of the experts.
Results: A total of 37 colorectal surgeons from 20 countries and 5 continents (Europe, Asia, North and South America, Australasia) contributed to the consensus. Participation to the iterative Delphi rounds was 100%. An expert radiologist, pathologist, and medical oncologist provided recommendations to maximize relevance to current practice. Consensus was obtained on all seven different chapters: patient selection and surgical indication, perioperative management, patient positioning and operating room set up, surgical technique, devices and instruments, pelvic anatomy, TaTME training, and outcomes analysis.
Conclusions: This multidisciplinary consensus statement achieved more than 80% approval and can thus be graded as strong recommendation, yet acknowledging the current lack of high level evidence. It provides the best possible guidance for safe implementation and practice of Transanal Total Mesorectal Excision.
Keywords: Guidelines; Oncology; Rectal cancer; Transanal total mesorectal excision.
Conflict of interest statement
Michel Adamina, Nicolas C. Buchs, Marta Penna and Roel Hompes have no conflicts of interest or financial ties to disclose.
References
-
- Deijen CL, Velthuis S, Tsai A, Mavroveli S, de Lange-de Klerk ES, Sietses C, Tuynman JB, Lacy AM, Hanna GB, Bonjer HJ. COLOR III: a multicentre randomised clinical trial comparing transanal TME versus laparoscopic TME for mid and low rectal cancer. Surg Endosc. 2016;30(8):3210–3215. doi: 10.1007/s00464-015-4615-x. - DOI - PMC - PubMed
-
- Evaluate Efficacy, Morbidity and Functional Outcome of Endoscopic TransAnal Proctectomy vs Standard Transabdominal Laparoscopic Proctectomy for Rectal Cancer (ETAP). GRECCAR 11. ClinicalTrials.gov Identifier: NCT02584985. Online website: https://clinicaltrials.gov/ct2/show/NCT02584985. Accessed: 30th August 2017
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
